Russia will supply the drug avifavir, designed for patients suffering from the new coronavirus a Argentina, Bolivia, Ecuador, Uruguay, Paraguay, Honduras and El Salvador, announced the Russian Direct Investment Fund (RDIF).
According to the RT agency, the agreement on sales in seven Latin American countries was signed between the state company Chrome, To the group Jimrar who created the drug and the Bolivian company Sigma Corp July 29.
The document provides for supply of a minimum of 150 thousand units of avifavir, and the Bolivian partner will receive the technology for preparing the medicine.
COVID is negative after four days of use
According to the Russian authorities, the drug “demonstrated high efficiency” during the first stage of clinical trials. In the first four days of treatment, 65 percent of the 40 patients who took Avifavir tested negative for COVID-19, and by the 10th day, the percentage of patients who tested negative increased to 90 percent.
However, the results are limited, because although the tests were carried out in 35 Russian medical centers, the drug (which since 2014 was used in Japan against the flu), only evaluated 700 patients.